GlassScriptPhysician profile
Allison Lumsden Lynch
NPI 1447821244
$4,884.76
in general payments reported to CMS, 2019-2025
40 companies · $1,435 in 2025
The $1,435 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $134 · 2022: $1,015 · 2023: $1,078 · 2024: $1,222 · 2025: $1,435.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,736.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,735.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $453.13 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $423.23 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $375.74 | 2022-2025 | Rexulti, Abilify Maintena |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $338.38 | 2021-2025 | Xifaxan, Trulance |
| Lilly USA, LLC | $296.99 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $271.04 | 2021-2025 | Repatha, Otezla, Otezla |
| Abbvie INC. | $253.19 | 2021-2025 | |
| Shield Therapeutics INC | $249.06 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $241.15 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Dexcom, INC. | $175.05 | 2023-2025 | Dexcom G6 Transmitter |
| Acadia Pharmaceuticals INC | $169.81 | 2025 | Daybue |
| Esperion Therapeutics, INC. | $142.82 | 2022-2024 | Nexletol |
| Sanofi-Aventis U.S. LLC | $118.18 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $95.68 | 2021-2024 | |
| Merck Sharp & Dohme LLC | $92.62 | 2021-2024 | Verquvo, Belsomra, Steglatro |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch Health US, LLC | $90.01 | 2022-2024 | Aplenzin, Wellbutrin |
| Sunovion Pharmaceuticals INC. | $89.44 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $81.27 | 2022-2024 | Synjardy, Tradjenta, Jardiance |
| Astellas Pharma US INC | $80.07 | 2023-2025 | Veozah |
| Corcept Therapeutics | $75.47 | 2022-2025 | Korlym |
| Kowa Pharmaceuticals America, INC. | $74.81 | 2022-2025 | Zoryve, Seglentis, Livalo |
| Xeris Pharmaceuticals, INC. | $74.42 | 2023 | Gvoke Hypopen |
| Lundbeck LLC | $69.13 | 2022-2024 | Rexulti |
| Glaxosmithkline, LLC. | $68.75 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Idorsia Pharmaceuticals US INC | $65.38 | 2022-2024 | Quviviq |
| Janssen Pharmaceuticals, INC | $65.17 | 2023-2025 | Xarelto, Spravato, Spectra |
| Biohaven Pharmaceutical Holding Company LTD. | $46.12 | 2022 | |
| Sumitomo Pharma America, INC. | $43.13 | 2023-2025 | Gemtesa |
| Corium, LLC | $32.61 | 2023 | Azstarys |
| Edwards Lifesciences Corporation | $31.33 | 2025 | Sapien 3 Ultra Resilia |
| Ardelyx, INC. | $31.10 | 2025 | Ibsrela |
| Biohaven Pharmaceuticals, INC. | $29.09 | 2021 | |
| Boston Scientific Corporation | $24.91 | 2025 | Accolade Sr |
| Actelion Pharmaceuticals US, INC. | $24.46 | 2025 | Opsumit, Uptravi |
| Supernus Pharmaceuticals, INC. | $22.66 | 2022 | |
| Mannkind Corporation | $18.35 | 2024 | |
| Amneal Pharmaceuticals LLC | $17.21 | 2022 | |
| Novartis Pharmaceuticals Corporation | $14.10 | 2023 | |
| Exact Sciences Corporation | $13.15 | 2023 | Cologuard Collection Kit |
| Genentech USA, INC. | $6.55 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allison Lynch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.